{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:48Z","timestamp":1791902688655,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13555-023-00997-x","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T14:08:52Z","timestamp":1694700532000},"page":"2621-2634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b\/3 Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tziotzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Serap","family":"Karada\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"2","key":"997_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"997_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"997_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. J Am Acad Dermatol. 2016;75(4):806\u2013812.e803.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"997_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556\u2013558.e551.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"997_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"JP Okhovat","year":"2019","unstructured":"Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;88(5):1040\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"997_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamadermatol.2022.6085","volume":"159","author":"S Lauron","year":"2023","unstructured":"Lauron S, Plasse C, Vaysset M, Pereira B, D'Incan M, Rondepierre F, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: A systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281\u20138.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"997_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"E Darwin","year":"2018","unstructured":"Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: Review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51\u201360.","journal-title":"Int J Trichology"},{"key":"997_CR8","doi-asserted-by":"crossref","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010; 62(2):177\u2013188, quiz 189\u201390.","DOI":"10.1016\/j.jaad.2009.10.032"},{"key":"997_CR9","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Alopecia areata Nat Rev Dis Primers"},{"issue":"2","key":"997_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: An Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"997_CR11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","volume":"55","author":"A Tosti","year":"2006","unstructured":"Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"997_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"A Alkhalifah","year":"2006","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part II. Treatment. J Am Acad Dermatol. 2010;62(2):191\u2013202, quiz 203\u2013194.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"997_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"997_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/exd.14155","volume":"29","author":"M Bertolini","year":"2020","unstructured":"Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703\u201325.","journal-title":"Exp Dermatol"},{"issue":"2","key":"997_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1087-0024.2003.00807.x","volume":"8","author":"R Paus","year":"2003","unstructured":"Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8(2):188\u201394.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"8","key":"997_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jid.2016.04.004","volume":"136","author":"EHC Wang","year":"2016","unstructured":"Wang EHC, Yu M, Breitkopf T, Akhoundsadegh N, Wang X, Shi FT, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136(8):1617\u201326.","journal-title":"J Invest Dermatol"},{"key":"997_CR17","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/DDDT.S172638","volume":"12","author":"K Triyangkulsri","year":"2018","unstructured":"Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323\u201335.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"997_CR18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/JCI31942","volume":"117","author":"A Gilhar","year":"2007","unstructured":"Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117(8):2019\u201327.","journal-title":"J Clin Invest"},{"key":"997_CR19","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"key":"997_CR20","doi-asserted-by":"crossref","unstructured":"Smith SE, Neier SC, Reed BK, Davis TR, Sinnwell JP, Eckel-Passow JE, et al. Multiplex matrix network analysis of protein complexes in the human TCR signalosome. Sci Sig. 2016;9(439):rs7.","DOI":"10.1126\/scisignal.aad7279"},{"key":"997_CR21","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","volume":"10","author":"F Solimani","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847.","journal-title":"Front Immunol"},{"issue":"9","key":"997_CR22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139.","journal-title":"Nat Med"},{"issue":"18","key":"997_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"997_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, et al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342.","journal-title":"ACS Chem Biol"},{"issue":"10387","key":"997_CR25","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"4","key":"997_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0095798420930932","volume":"46","author":"BE Weller","year":"2020","unstructured":"Weller BE, Bowen NK, Faubert SJ. Latent class analysis: A guide to best practice. J Black Psychol. 2020;46(4):287\u2013311.","journal-title":"J Black Psychol"},{"key":"997_CR27","doi-asserted-by":"crossref","unstructured":"Zhang X, Magnolo N, Mizuashi M, Mesinkovska N, Shapiro J, Zhang F, et al. Efficacy of ritlecitinib (PF-06651600) in patients with alopecia totalis and alopecia universalis: post hoc analysis of the ALLEGRO phase 2b\/3 study. Presented at EADV Congress. Abstract 581. 2022.","DOI":"10.25251\/skin.6.supp.102"},{"issue":"3","key":"997_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ygeno.2010.05.002","volume":"96","author":"RD Subramanya","year":"2010","unstructured":"Subramanya RD, Coda AB, Sinha AA. Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics. 2010;96(3):146\u201353.","journal-title":"Genomics"},{"key":"997_CR29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ebiom.2016.03.036","volume":"7","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, et al. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016;7:240\u20137.","journal-title":"EBioMedicine"},{"issue":"2","key":"997_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1468-3083.2008.02830.x","volume":"23","author":"E Kasumagic-Haliliovic","year":"2009","unstructured":"Kasumagic-Haliliovic E, Prohic A. Nail changes in alopecia areata: Frequency and clinical presentation. J Eur Dermatol Venereol. 2009;23(2):240\u20131.","journal-title":"J Eur Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00997-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:10:18Z","timestamp":1698487818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00997-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00997-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diamant Tha\u00e7i: consultant, investigator, speaker, and participant in scientific advisory boards for AbbVie, Almirall, Amgen, Biogen Idec, BMS, Janssen-Cilag, Galderma, Galapagos, LEO Pharma, Eli Lilly, New Bridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Sun\u00a0Pharma, and UCB; Christos Tziotzios: speaker for LEO Pharma; principal and chief investigator for Pfizer; and\u00a0consultant for Pfizer; Taisuke Ito: consultant, investigator, speaker, and participant in scientific advisory boards for Pfizer, Eli Lilly, Maruho, Meiji Seika Pharma, and Hisamitsu; Justin Ko: consultant, investigator, speaker, and participant in advisory boards for Eli Lilly, Pfizer, AbbVie, Arena, and Concert; Ay\u015fe Serap Karada\u011f: consultant, speaker, and\/or participant in scientific advisory boards for L\u2019Or\u00e9al, Novartis, AbbVie, Pfizer, UCB, and Abdi \u0130brahim; Hong Fang: nothing to report; Roger A. Edwards: employee\/owner of Health Services Consulting Corporation and paid consultant for Pfizer in connection with this study; Gianluca Bonfanti is an employee of Engineering Ingegneria Informatica, a paid sub-contractor to Health Services Consulting Corporation in conjunction with this study and development of this manuscript. Robert Wolk, Helen Tran, and Ernest Law are employees of Pfizer and hold stock or stock options in Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol was reviewed and approved by the institutional review boards or ethics committees of the participating institutions. The study was conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), International Council for Harmonisation Guideline for Good Clinical Practice, and the Declaration of Helsinki. All participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}